Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Andrey V. Khorinko"'
Autor:
Sergey M. Alexeev, Andrey V. Khorinko, Guzel Z. Mukhametshina, Konstantin G. Shelepen, Olga N. Burdaeva, Sergey A. Kulik, Chiradoni Thugappa Satheesh, Kirti Srivastava, Mummaneni Vikranth, Fedor Kryukov, Anastasia N. Paltusova, Mariya S. Shustova, Roman A. Ivanov
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
Abstract Background BCD-022 is a trastuzumab biosimilar which was shown to be equivalent to reference trastuzumab in a wide panel of physicochemical studies as well as preclinical studies in vitro and in vivo. International multicenter phase III clin
Externí odkaz:
https://doaj.org/article/91e85db418314c6180848ec4b818e417
Autor:
Konstantin G. Shelepen, Anastasia N. Paltusova, Fedor Kryukov, Sergey M. Alexeev, Mariya S. Shustova, Sergey A. Kulik, Kirti Srivastava, Chiradoni Thugappa Satheesh, Olga Burdaeva, Guzel Z. Mukhametshina, Andrey V. Khorinko, Roman Ivanov, Mummaneni Vikranth
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
BMC Cancer
BMC Cancer
Background BCD-022 is a trastuzumab biosimilar which was shown to be equivalent to reference trastuzumab in a wide panel of physicochemical studies as well as preclinical studies in vitro and in vivo. International multicenter phase III clinical tria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e583dc70946efde96993e08fa512bc31
https://doi.org/10.1186/s12885-020-07247-9
https://doi.org/10.1186/s12885-020-07247-9
Autor:
Aleksandr P. Pecheniy, Sergey A. Kulik, Oleg Gladkov, Daniil Stroyakovskiy, Sergey Odarchenko, Pavel Skopin, Grigory Adamchuk, Mikhail V. Kopp, Yurii Vinnyk, Rinat Galiulin, Andrey V. Khorinko, Jaroslav Kulyaba, Olga Filon, Sergey Orlov, Bogdan Kotiv, Sergiy Alekseev, Guzel Mukhametsina, Marina Matrosova, Olga Burdaeva, Sergei Tjulandin
Publikováno v:
Journal of Clinical Oncology. 33:8057-8057
8057 Background: BCD-021 demonstrated equivalence to Avastin in a comprehensive comparability exercise that included physicochemical, PK and PD studies, as well as phase I PK clinical study in pati...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9927074850ec7b2201e4a7cf50e9f2f5
https://doi.org/10.1200/jco.2015.33.15_suppl.8057
https://doi.org/10.1200/jco.2015.33.15_suppl.8057
Autor:
Aleksandr P. Pecheniy, Irina A. Jelvakova, Oleg Gladkov, Sergey Orlov, Nadezhda V. Kovalenko, Bogdan Kotiv, Andrey V. Khorinko, Marina Nechaeva, Tatiana I. Prokopenko, Ludmila P. Sheveleva, Julia S. Shapovalova, Olga Filon, Daniil L. Stroyakovsky, Olga Burdaeva, Sergei Tjulandin, Mikhail V. Kopp, Roman Ivanov
Publikováno v:
Journal of Clinical Oncology. 32:e13500-e13500
e13500 Background: BCD-021 is a bevacizumab biosimilar candidate manufactured by CJSC BIOCAD, Russia. Full spectrum of physicochemical and preclinical studies showed equivalence of BCD-021 to innov...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5d995f14ef6ad2b1865aedb78354525
https://doi.org/10.1200/jco.2014.32.15_suppl.e13500
https://doi.org/10.1200/jco.2014.32.15_suppl.e13500
Autor:
Tatiana I. Prokopenko, Roman Ivanov, Sergiy Alekseev, Julia S. Shapovalova, Olga Filon, Dmitry P. Udovitsa, Mikhail V. Kopp, Irina A. Jelvakova, Olga Burdaeva, Sergei Tjulandin, Marina Stenina, Mona Frolova, Ludmila P. Sheveleva, Daniil L. Stroyakovsky, Ekaterina Ignatova, Marina Nechaeva, Andrey V. Khorinko, Bogdan Kotiv
Publikováno v:
Journal of Clinical Oncology. 32:e11576-e11576
e11576 Background: BCD-022 is a trastuzumab biosimilar candidate manufactured by CJSC BIOCAD, Russia. Full spectrum of physicochemical and preclinical studies showed equivalence of BCD-022 to innov...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9bc53d722207e7a75790ab314707e576
https://doi.org/10.1200/jco.2014.32.15_suppl.e11576
https://doi.org/10.1200/jco.2014.32.15_suppl.e11576
Autor:
Roman Ivanov, Irina Koroleva, Olga V. Salafet, T. V. Chernovskaya, Olga Burdaeva, Andrey V. Khorinko, Elena G. Ovchinnikova, Ludmila P. Sheveleva, Tatiana I. Prokopenko, Marina Nechaeva, Marina Matrosova, Nadezhda V. Kovalenko
Publikováno v:
Journal of Clinical Oncology. 31:e20593-e20593
e20593 Background: Pegfilgrastim (conjugate of filgrastim and 20 kDa polyethylene glycol (PEG) is approved for treatment of chemotherapy-associated neutropenia. BCD-017 (empegfilgrastim) is a covalent conjugate of filgrastim with 30 kDa PEG. Increase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4badb1869bf025ec2d06496a5ec3b177
https://doi.org/10.1200/jco.2013.31.15_suppl.e20593
https://doi.org/10.1200/jco.2013.31.15_suppl.e20593
Autor:
Alexeev, Sergey M.1 (AUTHOR), Khorinko, Andrey V.2 (AUTHOR), Mukhametshina, Guzel Z.3 (AUTHOR), Shelepen, Konstantin G.4 (AUTHOR), Burdaeva, Olga N.5 (AUTHOR), Kulik, Sergey A.6 (AUTHOR), Satheesh, Chiradoni Thugappa7 (AUTHOR), Srivastava, Kirti8 (AUTHOR), Vikranth, Mummaneni9 (AUTHOR), Kryukov, Fedor10 (AUTHOR) kryukov@biocad.ru, Paltusova, Anastasia N.10 (AUTHOR), Shustova, Mariya S.10 (AUTHOR), Ivanov, Roman A.10 (AUTHOR)
Publikováno v:
BMC Cancer. 8/20/2020, Vol. 20 Issue 1, pN.PAG-N.PAG. 1p. 1 Diagram, 2 Charts, 1 Graph.